BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 10418981)

  • 1. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
    Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
    J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium.
    Labrie F; Labrie C; Bélanger A; Simard J; Giguère V; Tremblay A; Tremblay G
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):213-25. PubMed ID: 11850228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice.
    Gutman M; Couillard S; Roy J; Labrie F; Candas B; Labrie C
    Int J Cancer; 2002 May; 99(2):273-8. PubMed ID: 11979444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
    Simard J; Sanchez R; Poirier D; Gauthier S; Singh SM; Merand Y; Belanger A; Labrie C; Labrie F
    Cancer Res; 1997 Aug; 57(16):3494-7. PubMed ID: 9270018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro.
    Simard J; Labrie C; Bélanger A; Gauthier S; Singh SM; Mérand Y; Labrie F
    Int J Cancer; 1997 Sep; 73(1):104-12. PubMed ID: 9334816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.
    Li S; Lévesque C; Geng CS; Yan X; Labrie F
    Breast Cancer Res Treat; 1995 May; 34(2):147-59. PubMed ID: 7647332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
    Poulin R; Merand Y; Poirier D; Levesque C; Dufour JM; Labrie F
    Breast Cancer Res Treat; 1989 Oct; 14(1):65-76. PubMed ID: 2605344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.
    Martel C; Provencher L; Li X; St Pierre A; Leblanc G; Gauthier S; Mérand Y; Labrie F
    J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):199-205. PubMed ID: 9605415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
    Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
    Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen and aryl hydrocarbon responsiveness of ECC-1 endometrial cancer cells.
    Castro-Rivera E; Wormke M; Safe S
    Mol Cell Endocrinol; 1999 Apr; 150(1-2):11-21. PubMed ID: 10411295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
    MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
    Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.
    Schafer JI; Liu H; Tonetti DA; Jordan VC
    Cancer Res; 1999 Sep; 59(17):4308-13. PubMed ID: 10485477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
    Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI
    J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta.
    Tremblay A; Tremblay GB; Labrie C; Labrie F; Giguère V
    Endocrinology; 1998 Jan; 139(1):111-8. PubMed ID: 9421405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.
    Lazennec G; Katzenellenbogen BS
    Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context.
    Castro-Rivera E; Safe S
    J Steroid Biochem Mol Biol; 2003 Jan; 84(1):23-31. PubMed ID: 12648521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor.
    Zajchowski DA; Sager R; Webster L
    Cancer Res; 1993 Oct; 53(20):5004-11. PubMed ID: 8402691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basic guide to the mechanisms of antiestrogen action.
    MacGregor JI; Jordan VC
    Pharmacol Rev; 1998 Jun; 50(2):151-96. PubMed ID: 9647865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.